Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART

Linda Chang, Thomas Ernst, Mallory D. Witt, Nina Ames, Irwin Walot, Jorge Jovicich, Menaka DeSilva, Neha Trivedi, Oliver Speck, Eric N. Miller

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. Method: Thirty-three HIV patients naive to antiretroviral medications were evaluated before and 3 months after HAART using 1H-MRS and neuropsychological tests; results were compared with those of 26 seronegative control subjects. Results: Despite significant improvement in CD4 counts, and suppression of plasma and cerebrospinal fluid (CSF) viral loads, elevated brain metabolites (choline compounds and myoinositol in the frontal lobes) and neuropsychological tests abnormalities (including the computerized tests [CalCAP®]) persisted after 3 months of HAART. In the basal ganglia, choline and myoinositol became elevated only after treatment. No interaction effect was observed between the number of CSF-penetrating drugs (one vs two) and changes (baseline vs 3 months) in any of the brain metabolites, cognitive performance or CSF viral load. Conclusions: The persistent brain abnormalities suggest ongoing repair or reactive inflammatory processes in the brain after 3 months of HAART. Regimens with two CSF-penetrating antiretroviral medications do not appear to be more effective than those with one CSF-penetrating drug in treating HIV brain injury at 3 months.

Original languageEnglish
Pages (from-to)17-26
Number of pages10
JournalAntiviral Therapy
Volume8
Issue number1
Publication statusPublished - Feb 2003

Fingerprint

Highly Active Antiretroviral Therapy
Cerebrospinal Fluid
HIV
Neuropsychological Tests
Brain
Inositol
Choline
Viral Load
Brain Injuries
Frontal Lobe
CD4 Lymphocyte Count
Basal Ganglia
Pharmaceutical Preparations
Proton Magnetic Resonance Spectroscopy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Chang, L., Ernst, T., Witt, M. D., Ames, N., Walot, I., Jovicich, J., ... Miller, E. N. (2003). Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antiviral Therapy, 8(1), 17-26.

Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. / Chang, Linda; Ernst, Thomas; Witt, Mallory D.; Ames, Nina; Walot, Irwin; Jovicich, Jorge; DeSilva, Menaka; Trivedi, Neha; Speck, Oliver; Miller, Eric N.

In: Antiviral Therapy, Vol. 8, No. 1, 02.2003, p. 17-26.

Research output: Contribution to journalArticle

Chang, L, Ernst, T, Witt, MD, Ames, N, Walot, I, Jovicich, J, DeSilva, M, Trivedi, N, Speck, O & Miller, EN 2003, 'Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART', Antiviral Therapy, vol. 8, no. 1, pp. 17-26.
Chang L, Ernst T, Witt MD, Ames N, Walot I, Jovicich J et al. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antiviral Therapy. 2003 Feb;8(1):17-26.
Chang, Linda ; Ernst, Thomas ; Witt, Mallory D. ; Ames, Nina ; Walot, Irwin ; Jovicich, Jorge ; DeSilva, Menaka ; Trivedi, Neha ; Speck, Oliver ; Miller, Eric N. / Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. In: Antiviral Therapy. 2003 ; Vol. 8, No. 1. pp. 17-26.
@article{7092c55f22d0483e835427dc96eb113f,
title = "Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART",
abstract = "Background: Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. Method: Thirty-three HIV patients naive to antiretroviral medications were evaluated before and 3 months after HAART using 1H-MRS and neuropsychological tests; results were compared with those of 26 seronegative control subjects. Results: Despite significant improvement in CD4 counts, and suppression of plasma and cerebrospinal fluid (CSF) viral loads, elevated brain metabolites (choline compounds and myoinositol in the frontal lobes) and neuropsychological tests abnormalities (including the computerized tests [CalCAP{\circledR}]) persisted after 3 months of HAART. In the basal ganglia, choline and myoinositol became elevated only after treatment. No interaction effect was observed between the number of CSF-penetrating drugs (one vs two) and changes (baseline vs 3 months) in any of the brain metabolites, cognitive performance or CSF viral load. Conclusions: The persistent brain abnormalities suggest ongoing repair or reactive inflammatory processes in the brain after 3 months of HAART. Regimens with two CSF-penetrating antiretroviral medications do not appear to be more effective than those with one CSF-penetrating drug in treating HIV brain injury at 3 months.",
author = "Linda Chang and Thomas Ernst and Witt, {Mallory D.} and Nina Ames and Irwin Walot and Jorge Jovicich and Menaka DeSilva and Neha Trivedi and Oliver Speck and Miller, {Eric N.}",
year = "2003",
month = "2",
language = "English",
volume = "8",
pages = "17--26",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "1",

}

TY - JOUR

T1 - Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART

AU - Chang, Linda

AU - Ernst, Thomas

AU - Witt, Mallory D.

AU - Ames, Nina

AU - Walot, Irwin

AU - Jovicich, Jorge

AU - DeSilva, Menaka

AU - Trivedi, Neha

AU - Speck, Oliver

AU - Miller, Eric N.

PY - 2003/2

Y1 - 2003/2

N2 - Background: Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. Method: Thirty-three HIV patients naive to antiretroviral medications were evaluated before and 3 months after HAART using 1H-MRS and neuropsychological tests; results were compared with those of 26 seronegative control subjects. Results: Despite significant improvement in CD4 counts, and suppression of plasma and cerebrospinal fluid (CSF) viral loads, elevated brain metabolites (choline compounds and myoinositol in the frontal lobes) and neuropsychological tests abnormalities (including the computerized tests [CalCAP®]) persisted after 3 months of HAART. In the basal ganglia, choline and myoinositol became elevated only after treatment. No interaction effect was observed between the number of CSF-penetrating drugs (one vs two) and changes (baseline vs 3 months) in any of the brain metabolites, cognitive performance or CSF viral load. Conclusions: The persistent brain abnormalities suggest ongoing repair or reactive inflammatory processes in the brain after 3 months of HAART. Regimens with two CSF-penetrating antiretroviral medications do not appear to be more effective than those with one CSF-penetrating drug in treating HIV brain injury at 3 months.

AB - Background: Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. Method: Thirty-three HIV patients naive to antiretroviral medications were evaluated before and 3 months after HAART using 1H-MRS and neuropsychological tests; results were compared with those of 26 seronegative control subjects. Results: Despite significant improvement in CD4 counts, and suppression of plasma and cerebrospinal fluid (CSF) viral loads, elevated brain metabolites (choline compounds and myoinositol in the frontal lobes) and neuropsychological tests abnormalities (including the computerized tests [CalCAP®]) persisted after 3 months of HAART. In the basal ganglia, choline and myoinositol became elevated only after treatment. No interaction effect was observed between the number of CSF-penetrating drugs (one vs two) and changes (baseline vs 3 months) in any of the brain metabolites, cognitive performance or CSF viral load. Conclusions: The persistent brain abnormalities suggest ongoing repair or reactive inflammatory processes in the brain after 3 months of HAART. Regimens with two CSF-penetrating antiretroviral medications do not appear to be more effective than those with one CSF-penetrating drug in treating HIV brain injury at 3 months.

UR - http://www.scopus.com/inward/record.url?scp=12244255096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244255096&partnerID=8YFLogxK

M3 - Article

C2 - 12713060

AN - SCOPUS:12244255096

VL - 8

SP - 17

EP - 26

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 1

ER -